Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.
Rajith K R RajoliHenry PertinezUsman ArshadHelen BoxLee TathamPaul CurleyMegan NearyJoanne SharpNeill J LiptrottAnthony ValentijnChristopher A W DavidSteven P RannardGhaith AljayyoussiShaun H PenningtonAndrew HillMarta BoffitoStephen A WardSaye H KhooPatrick G BrayPaul M O'NeillW David HongGiancarlo A BiaginiAndrew OwenPublished in: British journal of clinical pharmacology (2020)
The PBPK model predicted tizoxanide concentrations within doses of nitazoxanide already given to humans previously. The reported dosing strategies provide a rational basis for design of clinical trials with nitazoxanide for the treatment or prevention of SARS-CoV-2 infection. A concordant higher dose of nitazoxanide is now planned for investigation in the seamless phase I/IIa AGILE trial.